IMMY - Imprimis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.22
+0.02 (+0.91%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close2.20
Open2.22
Bid2.16 x 1000
Ask2.26 x 800
Day's Range2.15 - 2.23
52 Week Range1.35 - 4.49
Volume41,191
Avg. Volume479,670
Market Cap46.285M
Beta1.48
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Does Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Salary Compare Well With Others?
    Simply Wall St.4 days ago

    Does Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Salary Compare Well With Others?

    Mark Baum took the helm as Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO and grew market cap to US$45.45M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • Associated Press2 months ago

    Imprimis reports 4Q loss

    The San Diego-based company said it had a loss of 13 cents per share. The pharmaceutical and drug compounding company posted revenue of $7.3 million in the period. For the year, the company reported that ...

  • Should You Be Content With Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Earnings Growth?
    Simply Wall St.2 months ago

    Should You Be Content With Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Earnings Growth?

    Measuring Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceedRead More...

  • Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)?
    Simply Wall St.3 months ago

    Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)?

    I am going to take a deep dive into Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...

  • What You Must Know About Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Financial Strength
    Simply Wall St.3 months ago

    What You Must Know About Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Financial Strength

    Investors are always looking for growth in small-cap stocks like Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), with a market cap of $33.27M. However, an important fact which most ignore is: how financiallyRead More...

  • Reuters3 months ago

    Imprimis receives FDA warning over eye medication advertising

    The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval. The Dec. 21 letter to San Diego-based Imprimis was posted on the FDA's website on Tuesday. Imprimis is contesting a lawsuit by rival Allergan Plc over allegations it is illegally selling and advertising unapproved drugs.

  • NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)
    Simply Wall St.3 months ago

    NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)

    Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), a USD$37.99M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population,Read More...

  • Is Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Pay Justified?
    Simply Wall St.4 months ago

    Is Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Pay Justified?

    Mark Baum is the CEO of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), which has recently grown to a market capitalization of $35.53M. Recognizing whether CEO incentives are aligned with shareholders is aRead More...

  • Capital Cube4 months ago

    ETFs with exposure to Imprimis Pharmaceuticals, Inc. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Imprimis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IMMY-US. Comparing the performance and risk of Imprimis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?
    Simply Wall St.5 months ago

    Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) track record on a high level, toRead More...

  • Associated Press5 months ago

    Imprimis reports 3Q loss

    The San Diego-based company said it had a loss of 28 cents per share. The pharmaceutical and drug compounding company posted revenue of $6.5 million in the period. The company's shares closed at $1.66. ...

  • Capital Cube5 months ago

    ETFs with exposure to Imprimis Pharmaceuticals, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Imprimis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IMMY-US. Comparing the performance and risk of Imprimis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • What’s The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)?
    Simply Wall St.7 months ago

    What’s The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)?

    Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) continues its loss-making streak, announcing a -$13.47M earnings for its latest financial year ending. Since IMMY is currently burning more cash than it is making, it’sRead More...

  • Capital Cube7 months ago

    ETFs with exposure to Imprimis Pharmaceuticals, Inc. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Imprimis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IMMY-US. Comparing the performance and risk of Imprimis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
    Capital Cube7 months ago

    Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Imprimis Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Imprimis Pharmaceuticals, Inc. – Akorn, Inc., Antares Pharma, Inc., Retractable Technologies, Inc., Delcath Systems, Inc., ICU Medical, Inc. and Tandem Diabetes Care, Inc. (AKRX-US, ATRS-US, RVP-US, DCTH-US, ICUI-US ... Read more (Read more...)

  • Associated Press8 months ago

    Imprimis posts 2Q profit

    On a per-share basis, the San Diego-based company said it had net income of 6 cents. The pharmaceutical and drug compounding company posted revenue of $6.9 million in the period. In the final minutes of ...

  • Forbes9 months ago

    FDA Links Naturopathic Turmeric Death To Contaminated Product

    A curcumin emulsion for injection made by compounding pharmacy ImprimisRx contained a dangerous impurity. The company formulates a variety of questionable products for intravenous use and pays a popular naturopathic doctor as a consultant.

  • Capital Cube11 months ago

    ETFs with exposure to Imprimis Pharmaceuticals, Inc. : June 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Imprimis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IMMY-US. Comparing the performance and risk of Imprimis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
    Capital Cube11 months ago

    Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017

    Categories: Yahoo FinanceGet free summary analysis Imprimis Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Imprimis Pharmaceuticals, Inc. – Akorn, Inc., Antares Pharma, Inc., Retractable Technologies, Inc., Delcath Systems, Inc., ICU Medical, Inc. and Tandem Diabetes Care, Inc. (AKRX-US, ATRS-US, RVP-US, DCTH-US, ICUI-US ... Read more (Read more...)

  • Imprimis Pharmaceuticals (IMMY) Looks Good: Stock Up 13%
    Zacks11 months ago

    Imprimis Pharmaceuticals (IMMY) Looks Good: Stock Up 13%

    Imprimis Pharmaceuticals, Inc. (IMMY) shares rose over 13% in the last trading session.

  • Associated Press11 months ago

    Imprimis reports 1Q loss

    The San Diego-based company said it had a loss of 26 cents per share. The pharmaceutical and drug compounding company posted revenue of $6.1 million in the period. In the final minutes of trading on Wednesday, ...